Synklino is developing SYN002, a CMV-specific immunotoxin designed to eliminate cytomegalovirus infections in transplant recipients by treating either the donor organ ex vivo or the recipient in vivo. This approach aims to significantly reduce the risk of CMV-related complications, thereby improving the quality of life for patients post-transplantation.
Funding
$48.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cytomegalovirus (CMV) infections pose a significant threat to transplant recipients, leading to complications, increased hospitalizations, and mortality. Current antiviral treatments primarily target active CMV infections and do not eliminate the latent virus, leaving patients vulnerable to reactivation. The lack of effective therapies to eradicate both active and latent CMV infections in donor organs contributes to suboptimal transplantation outcomes.
Solution
Synklino is developing SYN002, an immunotoxin designed to eliminate both active lytic and latent cytomegalovirus (CMV) infections in transplant recipients. SYN002 can be administered either ex vivo to treat the donor organ before transplantation or in vivo to treat the recipient after transplantation. This approach aims to reduce the risk of CMV-related complications by targeting CMV-infected cells directly, thereby improving the quality of life for patients post-transplantation. SYN002 is designed to be fast-acting, with full efficacy anticipated within the few hours that the organ is treated ex vivo. By eliminating CMV infection, Synklino aims to ensure a faster return to normal life for transplant patients.
Target Audience
The primary target audience includes transplant recipients and immunocompromised patients at risk of CMV infection, as well as clinicians and medical centers performing organ transplantation.
Features
- Fusion protein uniquely targeting both latent and lytic CMV-infected cells.
- Designed for ex vivo treatment of donor organs prior to transplantation or in vivo treatment of the recipient post-transplantation.
- Aims to eliminate the risk of CMV infection and reactivation in immunocompromised transplant recipients.
- Expected to be highly efficacious and potent compared to standard-of-care antiviral therapeutics.
- Demonstrated effectiveness in eliminating latent CMV-infected reservoirs in human organs in preclinical studies.
- GLP tox data supports targeted SYN002 ex-vivo therapy.
- SYN002 GMP drug product available to supply clinical development.